Ondine Biopharma Corporation
LSE : OBP

Ondine Biopharma Corporation

April 13, 2010 08:49 ET

Ondine Biopharma Corporation: AIM Notification

FOR:  ONDINE BIOPHARMA CORPORATION

TSX, AIM SYMBOL:  OBP

April 13, 2010

Ondine Biopharma Corporation: AIM Notification

VANCOUVER, BRITISH COLUMBIA--(Marketwire - April 13, 2010) - Ondine Biopharma Corporation (TSX:OBP)(AIM:OBP)
("Ondine" or the "Company") today announces the following transaction by a Director of the Company:

/T/

---------------------------------------------------------------------------
Name                                                           Merrill Biel
---------------------------------------------------------------------------
Relationship to the Company                                        Director
---------------------------------------------------------------------------
Date the transaction was reported to the Company              April 9, 2010
---------------------------------------------------------------------------
Nature of the transaction                              Options issued which
                                                      entitle the holder to
                                                     purchase common shares
                                                        under the Company's
                                                          stock option plan
---------------------------------------------------------------------------
Grant date                                                    April 9, 2010
---------------------------------------------------------------------------
Expiry date                                                   April 9, 2015
---------------------------------------------------------------------------
Number of options issued                                            200,000
---------------------------------------------------------------------------
Exercise price per option, each option
is exercisable into one common share                            Cdn. $0.075
---------------------------------------------------------------------------
Price per security issued in this transaction                           Nil
---------------------------------------------------------------------------
Nature and extent of the above's interest                       100% direct
in the transaction                                       ownership interest
---------------------------------------------------------------------------
Close period                                                             No
---------------------------------------------------------------------------
Additional information                           The options vest in stages
                                                      during the first year
                                                    after the date of grant
---------------------------------------------------------------------------

/T/

-30-

FOR FURTHER INFORMATION PLEASE CONTACT:

Ondine Biopharma Corporation
Carolyn Cross
Chairman and CEO
(604) 669-0555
ccross@ondinebiopharma.com
www.ondinebiopharma.com

OR

Canaccord Adams Ltd.
Ryan Gaffney
Nominated Adviser
+4420 7050 6500

-0-

Contact Information

  • Ondine Biopharma Corporation